“FDA registered” is not a substitute for “FDA approved.” The words identify different regulatory actions. A company can be registered or list a product without that record establishing FDA approval of the treatment being advertised. FDA's consumer guidance specifically cautions against confusing those categories. 1
The useful question is not whether a page displays an FDA-related phrase. It is which record applies to which product and use.
A compact reading guide
| Term in a claim | What the corresponding record concerns | What not to infer |
|---|---|---|
| Approved drug or biologic | A named product and its authorized labeling | Every disease or use involving the same scientific idea is approved |
| Device cleared through 510(k) | Substantial equivalence to a legally marketed predicate, under the applicable criteria | The device is identical to the predicate or clinically superior to alternatives |
| De Novo authorization | Classification and marketing route for a new low- or moderate-risk device type without a suitable predicate | A ranking showing it is better than every previously available device |
| Registered establishment or listed device | Registration/listing information | FDA endorsed the business or approved all its services |
The distinctions come from FDA's consumer, 510(k) and De Novo guidance. They are not a complete regulatory classification for every product category. 1 2 3
Clearance is a specific decision, not an insult
The 510(k) route centers on substantial equivalence to a predicate. The supporting evidence depends on the device and its differences; the phrase should not be turned into “no evidence was needed” or “it has proven superior clinical results.” Neither conclusion follows merely from the pathway name. 2
For a reader comparing devices, the actual intended use and evidence remain necessary. Two products can have different regulatory histories and still need a careful clinical comparison. A pathway label alone cannot perform that comparison.
De Novo does not mean “experimental forever”
FDA describes De Novo as a route for new device types for which general controls, or general and special controls, can provide reasonable assurance of safety and effectiveness. A granted request establishes the classification for the new type and can provide a predicate for later devices. 3
This is different from permission to begin a study. It is also different from a promise that every future revision, new indication or similar product has the same authorization. Our ARC-EX evidence report illustrates why intended population and measured function should stay attached to the specific record.
Product identity prevents the most important error
Consider an invented clinic page that displays a certificate for “Example Medical LLC” next to a claim about regrowing joints. Even if the establishment record is genuine, the display has not yet linked a particular product and intended use to the claimed authorization.
The missing chain is:
Offered product → manufacturer/model or drug identity → regulator record → actual intended use.
A careful comparison also checks the record's date and whether the advertised configuration is the one described. This is an evidence-matching exercise, not an accusation that every incomplete advertisement is fraudulent.
The Ryoncil report shows the problem in cell therapy. One genuine approval can coexist with unsupported claims made about other preparations. A general category such as “stem cells” cannot carry all the details needed to connect them.
A study identifier is not a marketing authorization
FDA's gene-therapy explanation distinguishes permission for an investigational study from the licensing route for marketing. A clinical-trial identifier tells a reader where a study is registered; it does not supply the missing marketing decision. 4
The right conclusion is bounded: “this is the listed study,” not “this treatment is approved because it appears in a government database.” Likewise, a paper reporting a result is evidence about that study, not an authorization document.
What this means for our coverage
Our reports name the regulator and jurisdiction rather than presenting “approved” as a worldwide status. They separate the authorized use from researchers' broader ambitions. We preserve historical dates so an old decision is not recirculated as a new approval.
This explainer does not evaluate an individual clinic or replace regulatory or legal advice. It supplies a vocabulary for examining the actual documents. Where a product record cannot be located or matched, that gap remains unresolved; it should not be filled by a logo or a guess.
Bottom line: the strongest evidence is the relevant record, not the most impressive-sounding word. Match identity and scope before turning a regulatory statement into a conclusion about treatment.
Continue with the next question
Generic, brand and biosimilar medicines: compare the prescription and the bill